Completed NA INTERVENTIONAL 2-arm NCT01767597

Application of HBV Rapid Tests as a Tool for Wide-Use Screening (OPTISCREEN-B)

Is the Combination of Screening Algorithms and Use of Hepatitis B Rapid Tests Useful in Optimizing the Screening and Prevention of Hepatitis B?

Sponsor: ANRS, Emerging Infectious Diseases

Conditions Carcinoma, Hepatocellular Hepatitis B Liver Cirrhosis

Interventions ELISA testing Rapid testing

Updated 7 times since 2017 Last updated: Oct 21, 2016 Started: Feb 29, 2012 Primary completion: Jul 31, 2012 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Carcinoma, Hepatocellular and Hepatitis B and is currently completed. ANRS, Emerging Infectious Diseases leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Dec 2021 — Jul 2024 [monthly]

Completed NA
Oct 2021 — Dec 2021 [monthly]

Completed NA
Jan 2021 — Oct 2021 [monthly]

Completed NA

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ANRS, Emerging Infectious Diseases
BioMérieux
Gilead Sciences
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Mairie de Paris
Roche Pharma AG

Data source: Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France